31

32

33

34
Juswinder SINGH, Shomir Ghosh, Arthur F Kluge, Russell C Petter: Heterocyclic compounds and uses thereof. Avila Therapeutics, Choate Hall & Stewart, December 4, 2008: US20080300268-A1

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


35
Juswinder Singh, Russell Colyn Petter, Dequiang Niu: Algorithm for designing irreversible inhibitors. Avila Therapeutics, McDermott Will & Emery, July 22, 2010: US20100185419-A1

The invention is an algorithm and method for designing an inhibitor that covalently binds a target polypeptide. The algorithm and method can be used to rapidly and efficiently convert reversible inhibitors into irreversible inhibitors.


36

37

38
Juswinder Singh, Shomir Ghosh, Arthur F Kluge, Russell C Petter, Richland W Tester: Heteroaryl compounds and uses thereof. Avila Therapeutics, September 22, 2011: US20110230494-A1

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


39
Juswinder Singh, Shomir Ghosh, Arthur F Kluge, Russell C Petter, Richland W Tester: Heteroaryl compounds and uses thereof. Avila Therapeutics, September 15, 2011: US20110224432-A1

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


40
Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu: Protein Kinase Conjugates and Inhibitors. Avila Therapeutics, May 19, 2011: US20110117073-A1

The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention al ...